AI is not eliminating clinical trial budget analyst roles - it is changing them. As protocol-to-budget automation improves, the profession is increasingly dividing into two distinct paths: reviewers who validate AI-generated budgets and strategists who focus on FMV, negotiations, country-specific costs, and stakeholder management.
Central vs. local lab assumptions are one of the fastest ways to either overbuild or underbuild a clinical trial budget. This article breaks down how to code each setup correctly, how mixed lab models should be handled, and which assumptions must be documented to avoid costly rework, sponsor pushback, and site payment issues.
Building and reviewing a clinical trial budget require two completely different modes of thinking. Builders translate ambiguity into momentum, while reviewers stress-test assumptions and look for hidden risk. When we try to apply both lenses at once, cognitive overload sets in and mistakes feel personal. Mastering the switch between builder and reviewer mindset is not about talent - it is about learning how to think in stages.
Clinical trial budgeting sits at the intersection of clinical, legal, finance, and operations. You will work with multiple stakeholders, each optimizing for different outcomes and understanding who owns what is critical for reducing friction, routing questions efficiently, and preventing delays during start-up.
